NEWSROOM
News Articles
![](https://bluejaydx.com/wp-content/uploads/2023/02/cfo_hiring_2-750x500-1-750x500.jpg)
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
ACTON, Mass./WEST WARWICK, R.I., February 16, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.
![](https://bluejaydx.com/wp-content/uploads/2021/10/aanalytics-750x500.jpg)
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.
![](https://bluejaydx.com/wp-content/uploads/2022/07/shutterstock_1656082015-2-750x500.jpg)
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test
![](https://bluejaydx.com/wp-content/uploads/2022/01/shutterstock_1694802769-750x500.jpg)
Bluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test
![](https://bluejaydx.com/wp-content/uploads/2021/10/aanalytics-750x500.jpg)
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.
![](https://bluejaydx.com/wp-content/uploads/2021/10/nw_v6_1-750x500.jpg)
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced…